Semaglutide vs Tirzepatide — Which Weight Loss Medication is Right for You?

If you've started researching medical weight loss, you've probably landed on the same question most patients ask: should I take semaglutide or tirzepatide? Both are injectable medications that have shown remarkable results in clinical trials. Both work on the GLP-1 pathway. But they're not identical — and the differences matter.

Here's a straightforward comparison from a physician's perspective.

How They Work

Semaglutide (brand names Wegovy and Ozempic) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut naturally releases after eating. GLP-1 slows gastric emptying, stimulates insulin release, and signals your brain that you've had enough food. Semaglutide does this more potently and for a longer duration than your natural hormone.

Tirzepatide (brand names Zepbound and Mounjaro) is a dual-action medication — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in insulin secretion and energy metabolism. By targeting both pathways simultaneously, tirzepatide has a different — and in many ways broader — mechanism of action.

Think of it this way: semaglutide turns one dial. Tirzepatide turns two.

Weight Loss: What the Data Shows

This is where most patients' attention goes, and the clinical trial data is clear:

Semaglutide (STEP trials):

• Average weight loss: 15-17% of body weight over 68 weeks
• At the highest dose (2.4 mg weekly), about one-third of patients lost 20% or more of their body weight

Tirzepatide (SURMOUNT trials):

• Average weight loss: 20-26% of body weight over 72 weeks, depending on dose
• At the highest dose (15 mg weekly), nearly 40% of patients lost 25% or more of their body weight

By the numbers, tirzepatide produces greater average weight loss. This is consistent across multiple trials and is likely related to the dual-receptor mechanism.

However, averages don't tell the full story. Individual responses vary significantly. Some patients respond better to semaglutide than tirzepatide, and vice versa. Genetics, baseline metabolic health, diet, exercise, and adherence all influence outcomes.

Side Effects

Both medications share similar side effect profiles, primarily gastrointestinal:

| Side Effect | Semaglutide | Tirzepatide |

|-------------|-------------|-------------|

| Nausea | 40-45% | 25-35% |

| Diarrhea | 25-30% | 15-25% |

| Constipation | 20-25% | 15-20% |

| Vomiting | 15-25% | 10-15% |

A few observations:

Nausea rates tend to be slightly lower with tirzepatide in clinical trials, which may be related to the GIP component (GIP has some anti-nausea properties). But individual experience varies — some patients tolerate semaglutide better.

Injection site reactions are generally mild with both medications.

Pancreatitis has been reported rarely with both medications. Patients with a history of pancreatitis should discuss this risk with their physician.

Gallbladder issues can occur with rapid weight loss on either medication. This is related to the weight loss itself, not the drug specifically.

Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Dosing and Titration

Semaglutide (Wegovy):

• Starting dose: 0.25 mg weekly for 4 weeks
• Titrated up through 0.5 mg, 1 mg, 1.7 mg
• Target dose: 2.4 mg weekly
• Full titration: approximately 16-20 weeks

Tirzepatide (Zepbound):

• Starting dose: 2.5 mg weekly for 4 weeks
• Titrated up through 5 mg, 7.5 mg, 10 mg, 12.5 mg
• Target dose: up to 15 mg weekly
• Full titration: approximately 20-28 weeks

Both are administered as once-weekly subcutaneous injections using prefilled auto-injector pens.

Cost and Insurance

This is often the deciding factor for patients:

Without insurance:

• Semaglutide (Wegovy): approximately $1,300-$1,700/month
• Tirzepatide (Zepbound): approximately $1,000-$1,200/month

With insurance: Coverage varies widely. Some commercial plans cover one but not the other. Prior authorizations are common. Medicare currently does not cover either medication for weight loss specifically.

Manufacturer savings programs exist for both medications and can significantly reduce out-of-pocket costs for commercially insured patients.

Compounded versions are available during FDA-declared shortages at significantly lower cost, though these come from compounding pharmacies rather than the original manufacturers. Quality and bioequivalence can vary, so physician oversight is important.

Beyond the Scale: Other Benefits

Both medications have demonstrated benefits beyond weight loss:

Semaglutide:

• The SELECT trial showed a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death)
• Improvements in blood pressure, cholesterol, and inflammatory markers
• Reduced liver fat (relevant for NAFLD/MASH)

Tirzepatide:

• Superior glycemic control in head-to-head trials against semaglutide for diabetes
• Improvements in obstructive sleep apnea severity
• Significant reductions in liver fat
• Cardiovascular outcomes trial (SURPASS-CVOT) results are pending

So Which One Should You Choose?

There's no universal "better" medication. The right choice depends on your individual situation:

Tirzepatide may be preferable if:

• You have a significant amount of weight to lose (BMI 35+)
• You have type 2 diabetes (dual mechanism provides superior glucose control)
• Cost is a factor (list price is currently lower)
• You've tried semaglutide without adequate response

Semaglutide may be preferable if:

• You have cardiovascular risk factors (proven CV benefit from SELECT trial)
• You prefer a more gradual titration
• Tirzepatide is unavailable due to shortages
• You've responded well to semaglutide previously

For many patients, the honest answer is: try one, give it adequate time at target dose, and if the response isn't sufficient, consider switching.

What Your Doctor Should Evaluate First

Before prescribing either medication, a thorough evaluation should include:

• Complete metabolic panel and lipid panel
• Hemoglobin A1c (even if you don't have diabetes)
• Thyroid function
• Assessment of current medications that may affect weight
• Review of contraindications
• Realistic discussion of expectations, side effects, and long-term use

This isn't a prescription you should get from a five-minute telehealth visit with a provider you'll never see again. These are serious medications that require ongoing physician oversight.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide (or vice versa)?

Yes. Patients who don't respond adequately to one medication or experience intolerable side effects can switch. Your physician will determine the appropriate starting dose of the new medication — you typically don't start at the lowest dose if you've already been on a GLP-1.

Do I need to be on one of these medications forever?

Current evidence suggests that long-term use is necessary to maintain weight loss for most patients. Obesity is a chronic disease, and these medications address the underlying biology. That said, some patients can reduce their dose over time while maintaining results, particularly if they've made substantial lifestyle changes.

Can I take both medications together?

No. Semaglutide and tirzepatide should not be combined. They work on overlapping pathways, and using both would increase side effect risk without proven additional benefit.

Which one is better for someone without diabetes?

Both are FDA-approved for weight management regardless of diabetes status. Tirzepatide tends to produce greater average weight loss, but semaglutide has proven cardiovascular benefits. Your physician can help weigh these factors based on your health profile.

---

At CORAL, Dr. Tae Y. Kim, DO, evaluates each patient individually to determine which weight loss medication — if any — is the right fit. We offer telehealth consultations across Florida so you can get started from home. [Book your consultation](/start) to discuss your options.